^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BZD1901

    i
    Other names: BZD1901, αPD1-MSLN-CAR T Cells, autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies, autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells, BZD-1901, PD-1 antibody expressing mesoCAR-T cells, αPD-1-mesoCAR-T, BZDS1901, BZD 1901
    Associations

    News

    Trials
    Company:
    Shanghai Cell Therapy Group
    Drug class:
    PD1 inhibitor, Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Cell Therapy Group Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> Jan 2025 | Trial primary completion date: Dec 2022 --> Jul 2024
    Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    PD-L1 expression
    |
    BZD1901
    over1year
    Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Shanghai Cell Therapy Group Co.,Ltd
    New P1/2 trial • CAR T-Cell Therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    PD-L1 expression
    |
    BZD1901
    over1year
    Non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial (AACR 2023)
    After apheresis and lymphodepletion with cyclophosphamide and fludarabine... PD-1 nanobody secreted and MSLN targeting CAR-T cells have demonstrated promising efficacy on MPM patients. Besides CAR-T direct tumor killing activity, secreted PD-1 nanobodies may provide additional clinical benefit by invigorating CAR-T from PD-L1 inhibition, activating TILs and relieving local immunosuppression.
    Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • MSLN (Mesothelin)
    |
    PD-L1 expression • MSLN expression
    |
    cyclophosphamide • fludarabine IV • BZD1901
    2years
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=21, Recruiting, Shanghai Mengchao Cancer Hospital | Trial completion date: Sep 2022 --> Aug 2023 | Trial primary completion date: Jun 2022 --> Feb 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • MSLN (Mesothelin) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression
    |
    BZD1901
    over2years
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=21, Recruiting, Shanghai Mengchao Cancer Hospital
    New P1 trial • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression
    |
    BZD1901
    3years
    Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Cell Therapy Group Co.,Ltd
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    PD-L1 expression
    |
    BZD1901
    over4years
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai Cell Therapy Group Co.,Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    PD-L1 expression
    |
    BZD1901
    over4years
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Wuhan Union Hospital, China
    New P1 trial • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    PD-L1 expression
    |
    BZD1901